ArticleMicrobial cell factories2026
Enhanced rhamnolipid production in Pseudomonas aeruginosa 8D by systematic genetic engineering.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Rhamnolipids are environmentally friendly biosurfactants primarily produced by Pseudomonas aeruginosa. The complex and tightly regulated network imposes limitations on rhamnolipid biosynthesis. Therefore, rational genetic engineering of P. aeruginosa to optimize metabolic flux holds significant promise for enhancing rhamnolipid production. A strain designated P. aeruginosa 8D was isolated and found to produce higher levels of rhamnolipids compared to the model strain PAO1. Promoter activity analysis revealed that the expression levels of regulatory genes rhlR and rhlI, biosynthetic genes rhlAB and rhlC, and the precursor synthesis gene algC were all significantly higher in 8D. To further enhance rhamnolipid production, we performed stepwise genetic modifications in 8D. First, deletion of two restriction modification (RM) systems, RM1 and RM2, led to a 4–6-fold increase in transformation efficiency. Next, the regulatory gene exsA of the type III secretion system (T3SS) was knocked out for reducing the strain’s pathogenicity. Subsequently, we disrupted the exopolysaccharide biosynthesis gene clusters pslA-O, algD-F, and pelA-G, which compete for metabolic precursors required for rhamnolipid synthesis. The engineered strain ΔRM1-RM2-exsA-pslA-O-algD-F-pelA-G produced 14.53 g/L of rhamnolipids, compared to 8.567 g/L for the wild-type 8D strain. To further boost production, we overexpressed rhlAB using two complementary approaches. The IPTG-inducible plasmid pMMB67EH-rhlAB increased rhamnolipid production 2.64-fold compared to 8D (pMMB67EH), reaching a final titer of 22.134 g/L, whereas chromosomal integration of CTX-rhlAB enabled stable expression and achieved 16.98 g/L of rhamnolipids, a 2.02-fold increase over 8D. This work presents a rational engineering strategy integrating reduced virulence and metabolic rewiring, offering a safe and efficient P. aeruginosa chassis for economical rhamnolipid production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.